Christelle de la Fouchardière1, Myriam Decaussin-Petrucci2, Julien Berthiller3, Françoise Descotes4, Jonathan Lopez4, Jean-Christophe Lifante5, Jean-Louis Peix5, Anne-Laure Giraudet6, Armelle Delahaye7, Sandrine Masson7, Claire Bournaud-Salinas8, Françoise Borson Chazot7. 1. Medical Oncology Department, Centre Leon Berard, University Lyon I, Lyon, France. Electronic address: christelle.delafouchardiere@lyon.unicancer.fr. 2. Pathology Department, Hospital Lyon-Sud, University Lyon I, Pierre-Bénite, France. 3. Epidemiology, Pharmacology and Clinical Investigations, Mother Child Hospital, Bron; University Lyon I, Lyon, France. 4. Biochemistry and Molecular Biology Department, Hospital Lyon-Sud, University Lyon I, Lyon, Pierre-Bénite, France. 5. Department of General and Endocrine Surgery, University Hospital Lyon-Sud, Lyon, France. 6. Department of Nuclear Medicine Centre Leon Berard, University Lyon I, Lyon, France. 7. Endocrinology Department-INSERM, UMR 1052, University Lyon I, Lyon, France. 8. Department of Nuclear Medicine, Hospital Louis Pradel, University Lyon I, Bron, France.
Abstract
BACKGROUND: The prognosis of poorly differentiated thyroid carcinomas (PDTC) is heterogeneous though generally poor. The objectives of this study were to identify clinical and molecular factors of poor prognosis. METHODS: One hundred four consecutive patients treated for a PDTC between 01/01/2000 and 31/12/2010 were included in this study. A pathological review was done for all cases (blinded to clinical data and outcome). RESULTS: All patients underwent thyroidectomy. Adjuvant radioactive-iodine was administered in 95.2% of them. Tumours were pT3 or pT4 in 68.3% of cases and metastatic in 38.5% of patients. Extrathyroidal extension (ETE) was observed in 40% of patients. At the end of the initial treatment, only 37% of patients were considered in remission. Fifty-two patients (50%) became refractory to radioiodine during follow-up. The 5-year overall survival was 72.8% and the 5-year recurrence-free survival (RFS) was 45.3%. Remission after initial treatment was an independent factor of RFS (HR = 0.22; [0.10-0.49]). ETE was the only significant parameter influencing the overall survival in multivariate analysis. TERT promoter mutations at positions -124 (C228T) and -146 (C250T) were present in 38.1% of analysed patients and significantly associated with radioiodine resistance but not with overall survival. Half of TERT promoter mutant tumours harboured also RAS or BRAF mutations. CONCLUSION: PDTC form a heterogeneous group of patients with usual late-stage diagnosis, low radioactive iodine avidity and frequent metastatic spread. TERT promoter mutations could help to identify patients with high risk of radio-iodine refractoriness.
BACKGROUND: The prognosis of poorly differentiated thyroid carcinomas (PDTC) is heterogeneous though generally poor. The objectives of this study were to identify clinical and molecular factors of poor prognosis. METHODS: One hundred four consecutive patients treated for a PDTC between 01/01/2000 and 31/12/2010 were included in this study. A pathological review was done for all cases (blinded to clinical data and outcome). RESULTS: All patients underwent thyroidectomy. Adjuvant radioactive-iodine was administered in 95.2% of them. Tumours were pT3 or pT4 in 68.3% of cases and metastatic in 38.5% of patients. Extrathyroidal extension (ETE) was observed in 40% of patients. At the end of the initial treatment, only 37% of patients were considered in remission. Fifty-two patients (50%) became refractory to radioiodine during follow-up. The 5-year overall survival was 72.8% and the 5-year recurrence-free survival (RFS) was 45.3%. Remission after initial treatment was an independent factor of RFS (HR = 0.22; [0.10-0.49]). ETE was the only significant parameter influencing the overall survival in multivariate analysis. TERT promoter mutations at positions -124 (C228T) and -146 (C250T) were present in 38.1% of analysed patients and significantly associated with radioiodine resistance but not with overall survival. Half of TERT promoter mutant tumours harboured also RAS or BRAF mutations. CONCLUSION: PDTC form a heterogeneous group of patients with usual late-stage diagnosis, low radioactive iodine avidity and frequent metastatic spread. TERT promoter mutations could help to identify patients with high risk of radio-iodine refractoriness.
Authors: Alyaksandr V Nikitski; Susan L Rominski; Vincenzo Condello; Cihan Kaya; Mamta Wankhede; Federica Panebianco; Hong Yang; Daniel L Altschuler; Yuri E Nikiforov Journal: Thyroid Date: 2019-08-16 Impact factor: 6.568
Authors: Gustavo C Penna; Ana Pestana; José Manuel Cameselle; Denise Momesso; Fernanda Accioly de Andrade; Ana Paula Aguiar Vidal; Mario Lucio Araujo Junior; Miguel Melo; Priscila Valverde Fernandes; Rossana Corbo; Mario Vaisman; Manuel Sobrinho-Simões; Paula Soares; Fernanda Vaisman Journal: Endocrine Date: 2018-06-15 Impact factor: 3.633
Authors: Anna Anschlag; Brandon H Greene; Lorianna KÖnneker; Markus Luster; James Nagarajah; Sabine WÄchter; Annette Wunderlich; Andreas Pfestroff Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Agnieszka Walczyk; Janusz Kopczyński; Danuta Gąsior-Perczak; Iwona Pałyga; Artur Kowalik; Magdalena Chrapek; Maria Hejnold; Stanisław Góźdź; Aldona Kowalska Journal: PLoS One Date: 2020-02-24 Impact factor: 3.240
Authors: Thomas Crezee; Marika H Tesselaar; Martin Jaeger; Katrin Rabold; Willem E Corver; Hans Morreau; Adriana C H Van Engen-Van Grunsven; Jan W A Smit; Romana T Netea-Maier; Theo S Plantinga Journal: Oncol Lett Date: 2021-06-06 Impact factor: 2.967